$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011404 Filed on March 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$3.603M	$100.0M	$18.22M
YoY Change	-37.98%	55148.62%	8.2%
Cost Of Revenue	$684.0K	$954.0K	$6.512M
YoY Change	-50.29%	148.44%	47.5%
Gross Profit	$2.919M	$3.885M	$11.71M
YoY Change	-34.15%	-2013.79%	-5.76%
Gross Profit Margin	81.02%	3.89%	64.26%
Selling, General & Admin	$5.169M	$5.882M	$26.61M
YoY Change	-30.82%	-42.1%	-62.78%
% of Gross Profit	177.08%	151.4%	227.35%
Research & Development	$594.0K	$1.383M	$2.939M
YoY Change	10.0%	-18.17%	-88.26%
% of Gross Profit	20.35%	35.6%	25.11%
Depreciation & Amortization	$12.00K	$22.00K	$477.0K
YoY Change	-95.1%	-91.2%	-53.0%
% of Gross Profit	0.41%	0.57%	4.07%
Operating Expenses	$5.763M	$7.265M	$29.55M
YoY Change	-28.07%	-38.69%	-69.39%
Operating Profit	-$2.844M	-$3.380M	-$17.85M
YoY Change	-20.54%	-71.95%	-78.78%
Interest Expense	$564.0K	$1.853M	$2.270M
YoY Change	-0.18%	-58.72%	4.32%
% of Operating Profit
Other Income/Expense, Net	-$1.965M	-$587.0K	$70.84M
YoY Change	-260.02%	-23.27%	848.37%
Pretax Income	-$4.809M	-$2.114M	$53.00M
YoY Change	104.55%	-74.62%	-169.14%
Income Tax		$0.00	$17.00K
% Of Pretax Income			0.03%
Net Earnings	-$4.809M	-$5.098M	$52.98M
YoY Change	104.29%	-55.59%	-169.07%
Net Earnings / Revenue	-133.47%	-5.1%	290.81%
Basic Earnings Per Share	-$0.16		$10.36
Diluted Earnings Per Share	-$0.16	-$0.43	$0.05
COMMON SHARES
Basic Shares Outstanding	45.94M shares	10.73M shares	4.827M shares
Diluted Shares Outstanding	31.19M shares		984.0M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Cash & Equivalents			$0.00
Short-Term Investments
Other Short-Term Assets	$1.311M	$1.775M	$1.775M
YoY Change	-56.2%	-48.18%	-48.18%
Inventory	$1.306M	$1.697M	$1.697M
Prepaid Expenses
Receivables	$4.306M	$5.738M	$5.738M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.923M	$9.210M	$9.210M
YoY Change	-58.08%	-27.47%	-27.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.200M	$1.203M	$1.309M
YoY Change	-67.55%	-69.47%	-84.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$35.00K	$35.00K	$35.00K
YoY Change	-98.18%	-99.15%	-99.15%
Total Long-Term Assets	$1.294M	$1.344M	$1.344M
YoY Change	-86.41%	-89.22%	-89.22%
TOTAL ASSETS
Total Short-Term Assets	$6.923M	$9.210M	$9.210M
Total Long-Term Assets	$1.294M	$1.344M	$1.344M
Total Assets	$8.217M	$10.55M	$10.55M
YoY Change	-68.44%	-58.06%	-58.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.29M	$17.02M	$17.02M
YoY Change	-13.32%	13.59%	13.59%
Accrued Expenses	$4.575M	$4.227M	$6.933M
YoY Change	32.46%	2.5%	-19.48%
Deferred Revenue	$3.200M	$3.200M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$42.35M	$43.27M	$43.27M
YoY Change	-16.36%	-34.13%	-34.13%
Total Short-Term Liabilities	$74.24M	$72.46M	$72.46M
YoY Change	-6.98%	-22.77%	-22.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.000K	$8.000K	$8.000K
YoY Change	-99.85%	-99.74%	-99.74%
Total Long-Term Liabilities	$4.000K	$8.000K	$8.000K
YoY Change	-99.85%	-99.74%	-99.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$74.24M	$72.46M	$72.46M
Total Long-Term Liabilities	$4.000K	$8.000K	$8.000K
Total Liabilities	$74.24M	$72.47M	$72.47M
YoY Change	-9.94%	-25.26%	-25.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$893.6M	-$888.7M
YoY Change	-5.04%	-5.33%
Common Stock	$5.000K	$2.000K
YoY Change	-100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$70.67M	-$66.51M	-$61.92M
YoY Change
Total Liabilities & Shareholders Equity	$8.217M	$10.55M	$10.55M
YoY Change	-68.44%	-58.06%	-58.06%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.809M	-$5.098M	$52.98M
YoY Change	104.29%	-55.59%	-169.07%
Depreciation, Depletion And Amortization	$12.00K	$22.00K	$477.0K
YoY Change	-95.1%	-91.2%	-53.0%
Cash From Operating Activities	$123.0K	-$170.0K	-$8.968M
YoY Change	-102.49%	-97.4%	-87.26%
INVESTING ACTIVITIES
Capital Expenditures	$14.00K	$0.00	$4.000K
YoY Change	366.67%	-100.0%	-98.83%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$14.00K	$0.00	-$4.000K
YoY Change	366.67%	-100.0%	-98.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net			$1.154M
YoY Change			-80.41%
Cash From Financing Activities		340.0K	$4.776M
YoY Change		-77.33%	-92.29%
NET CHANGE
Cash From Operating Activities	$123.0K	-170.0K	-$8.968M
Cash From Investing Activities	-$14.00K	0.000	-$4.000K
Cash From Financing Activities		340.0K	$4.776M
Net Change In Cash	$109.0K	170.0K	-$4.196M
YoY Change	-103.36%	-103.36%	-52.38%
FREE CASH FLOW
Cash From Operating Activities	$123.0K	-$170.0K	-$8.968M
Capital Expenditures	$14.00K	$0.00	$4.000K
Free Cash Flow	$109.0K	-$170.0K	-$8.972M
YoY Change	-102.21%	-97.41%	-87.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022	EVFM	Reclassification Adjustment Related To Debt Extinguishment ReclassificationAdjustmentRelatedToDebtExtinguishment		usd
CY2022	EVFM	Exchange Of Series B2 Convertible Preferred Stock Value ExchangeOfSeriesB2ConvertiblePreferredStockValue		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures		usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023	EVFM	Adjustment Related To Reverse Stock Split AdjustmentRelatedToReverseStockSplit		usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature		usd
CY2023	EVFM	Financial Instrument Modification Expense FinancialInstrumentModificationExpense		usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease		usd
CY2023	EVFM	Financial Instrument Expense Noncash FinancialInstrumentExpenseNoncash		usd
CY2022	EVFM	Gain Loss On Accounts Payable Settlements GainLossOnAccountsPayableSettlements		usd
CY2023	EVFM	Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts		usd
CY2023	EVFM	Proceeds From Issuance Of Common Stock The Offering ProceedsFromIssuanceOfCommonStockTheOffering		usd
CY2023	EVFM	Proceeds From Issuance Of Preferred Stock Registered Direct Offering ProceedsFromIssuanceOfPreferredStockRegisteredDirectOffering		usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings		usd
CY2022	EVFM	Exchange Of Convertible Notes To Series E1 Shares ExchangeOfConvertibleNotesToSeriesE1Shares		usd
CY2022	EVFM	Exchange Of Warrants And Partial Purchase Rights Value To Series F1 Shares ExchangeOfWarrantsAndPartialPurchaseRightsValueToSeriesF1Shares		usd
CY2022	EVFM	Series E1 Shares Dividends SeriesE1SharesDividends		usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2023	EVFM	Temporary Equity Value Exchange Of Convertible Securities TemporaryEquityValueExchangeOfConvertibleSecurities		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	EVFM	Exchange Of Adjuvant Notes To Purchase Rights ExchangeOfAdjuvantNotesToPurchaseRights		usd
CY2023	EVFM	Exchange Of Term Notes To Purchase Rights ExchangeOfTermNotesToPurchaseRights		usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent		usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent		usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent		usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q4	EVFM	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	EVFM	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledIntrinsicValue		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023	EVFM	Defined Contribution Plan Period Required Before Participation DefinedContributionPlanPeriodRequiredBeforeParticipation	P3M
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations		usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	City Area Code CityAreaCode	(858)
CY2023	dei	Local Phone Number LocalPhoneNumber	550-1900
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	EVFM
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1900000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45939509	shares
CY2023	dei	Auditor Firm AuditorFirmId	207
CY2022	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	BPM, LLP
CY2023	dei	Auditor Location AuditorLocation	Walnut Creek, California
CY2022	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2022	dei	Auditor Location AuditorLocation	San Diego, CA
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2769000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	580000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1207000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5738000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1126000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1697000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5379000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1195000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2218000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	9210000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	12699000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1203000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3940000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	106000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4406000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4118000	usd
CY2023Q4	us-gaap	Assets Assets	10554000	usd
CY2022Q4	us-gaap	Assets Assets	25163000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17020000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14984000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	14731000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	39416000	usd
CY2023Q4	EVFM	Convertible Notes Payable Current Adjuvant ConvertibleNotesPayableCurrentAdjuvant	28537000	usd
CY2022Q4	EVFM	Convertible Notes Payable Current Adjuvant ConvertibleNotesPayableCurrentAdjuvant	26268000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3316000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2876000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	93830000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3133000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	96963000	usd
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6512000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4415000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2939000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25032000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11664000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	43951000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27563000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-17847000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	31000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	85000	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	2628000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	2087000	usd
CY2023	EVFM	Gain Loss On Issuance Of Financial Instruments GainLossOnIssuanceOfFinancialInstruments	-6776000	usd
CY2022	EVFM	Gain Loss On Issuance Of Financial Instruments GainLossOnIssuanceOfFinancialInstruments	-72993000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	75337000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-24487000	usd
CY2023	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	4879000	usd
CY2022	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	106952000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	70843000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7470000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	52996000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76654000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	52979000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-76698000	usd
CY2023	EVFM	Deemed Dividends DeemedDividends	2984000	usd
CY2022	EVFM	Deemed Dividends DeemedDividends	1316000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	49995000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-78014000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	10.36
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-167.42
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-167.42
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4826763	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	465967	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	984038574	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	465967	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	52979000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-76698000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	22814000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	44438000	usd
CY2023	EVFM	Reclassification Adjustment Related To Debt Extinguishment ReclassificationAdjustmentRelatedToDebtExtinguishment	-73187000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2606000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32260000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-104315000	usd
CY2022	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	7953000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1239000	usd
CY2022	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	41932000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	20000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3408000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1005000	usd
CY2022	EVFM	Stock Issued During Period Value Conversion Of Convertible Preferred Stock StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock	1251000	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	81000	usd
CY2022	EVFM	Stock Issued During Period Value Exchange Transaction StockIssuedDuringPeriodValueExchangeTransaction	2339000	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	18000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	1344000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	44438000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1070000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3313000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-76698000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-71800000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-71800000	usd
CY2023	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	284000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	426000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	5420000	usd
CY2023	EVFM	Issuance Of Convertible And Redeemable Preferred Stock Upon Exchange Of Notes With Existing Equityholders IssuanceOfConvertibleAndRedeemablePreferredStockUponExchangeOfNotesWithExistingEquityholders	-1800000	usd
CY2023	EVFM	Issuance Of Convertible And Redeemable Preferred Stock Upon Exchange Of Partial Purchase Rights Value And Warrants IssuanceOfConvertibleAndRedeemablePreferredStockUponExchangeOfPartialPurchaseRightsValueAndWarrants	-2761000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	22814000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1189000	usd
CY2023	EVFM	Reverse Of Accumulated Other Comprehensive Income Loss ReverseOfAccumulatedOtherComprehensiveIncomeLoss	-73187000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	74000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	52979000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	52979000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-66510000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-66510000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	52979000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-76698000	usd
CY2023	EVFM	Gain Loss On Issuance Of Financial Instruments GainLossOnIssuanceOfFinancialInstruments	-6776000	usd
CY2022	EVFM	Gain Loss On Issuance Of Financial Instruments GainLossOnIssuanceOfFinancialInstruments	-72993000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	75337000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-24487000	usd
CY2023	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	4879000	usd
CY2022	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	106952000	usd
CY2022	EVFM	Financial Instrument Modification Expense FinancialInstrumentModificationExpense	1067000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1189000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3313000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	477000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1015000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2270000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2176000	usd
CY2023	EVFM	Noncash Rightofuse Amortization NoncashRightofuseAmortization	1304000	usd
CY2022	EVFM	Noncash Rightofuse Amortization NoncashRightofuseAmortization	1031000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1576000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	-300000	usd
CY2023	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	466000	usd
CY2022	EVFM	Financial Instrument Expense Noncash FinancialInstrumentExpenseNoncash	514000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2511000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-926000	usd
CY2023	EVFM	Gain Loss On Accounts Payable Settlements GainLossOnAccountsPayableSettlements	2096000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4612000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5323000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2106000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1566000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3661000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2593000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4090000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4474000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	527000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4106000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	434000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2478000	usd
CY2023	EVFM	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1478000	usd
CY2022	EVFM	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1354000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8968000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70410000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	341000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-341000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	290000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	25211000	usd
CY2022	EVFM	Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts	24882000	usd
CY2022	EVFM	Proceeds From Issuance Of Common Stock The Offering ProceedsFromIssuanceOfCommonStockTheOffering	7438000	usd
CY2022	EVFM	Proceeds From Issuance Of Preferred Stock Registered Direct Offering ProceedsFromIssuanceOfPreferredStockRegisteredDirectOffering	20000	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5640000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	11500000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1154000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5892000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	18000	usd
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1202000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4776000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61939000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4196000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8812000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4776000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13588000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	580000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4776000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	338000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	698000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	26000	usd
CY2023	EVFM	Exchange Of Convertible Notes To Series E1 Shares ExchangeOfConvertibleNotesToSeriesE1Shares	1800000	usd
CY2023	EVFM	Exchange Of Warrants And Partial Purchase Rights Value To Series F1 Shares ExchangeOfWarrantsAndPartialPurchaseRightsValueToSeriesF1Shares	2761000	usd
CY2023	EVFM	Issuance Of Common Stock Upon Exercise Of Purchase Rights IssuanceOfCommonStockUponExerciseOfPurchaseRights	426000	usd
CY2022	EVFM	Issuance Of Common Stock Upon Exercise Of Purchase Rights IssuanceOfCommonStockUponExerciseOfPurchaseRights	1007000	usd
CY2023	EVFM	Series E1 Shares Dividends SeriesE1SharesDividends	74000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	219000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	105000	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1187000	usd
CY2022	EVFM	Temporary Equity Value Exchange Of Convertible Securities TemporaryEquityValueExchangeOfConvertibleSecurities	1616000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	3412000	usd
CY2022	EVFM	Exchange Of Adjuvant Notes To Purchase Rights ExchangeOfAdjuvantNotesToPurchaseRights	634000	usd
CY2022	EVFM	Exchange Of Term Notes To Purchase Rights ExchangeOfTermNotesToPurchaseRights	4806000	usd
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	a reverse stock split between 1-for-20 and not more than 1-for-125 at any time on or prior to March 15, 2024. The Company decided on a ratio of 1-for-125 for the Reverse Stock Split, which became effective on May 18, 2023.
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	600000	usd
CY2023Q4	EVFM	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	63300000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-888700000	usd
CY2022Q4	us-gaap	Share Price SharePrice	0.01
CY2022Q4	us-gaap	Share Price SharePrice	0.01
CY2023	EVFM	Milestone Method Revenue Recognized MilestoneMethodRevenueRecognized	100000000.0	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zwk33GFixG02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zMRsVtnI20Hj">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the discount rate used in estimating the fair value of the right<b>-</b>of<b>-</b>use (ROU) assets and lease liabilities; the assumptions used in estimating the fair value of convertible notes, warrants and purchase rights issued; the useful lives of property and equipment; the recoverability of long-lived assets; clinical trial accruals; the assumptions used in estimating the fair value of stock-based compensation expense; the valuation of inventory; and the valuation of deferred tax assets. These assumptions are more fully described in <a href="#ak_001">Note 2 – Summary of Significant Accounting Policies</a>, <a href="#ak_002">Note 3 - Revenue</a>, <a href="#ak_003">Note 4 - Debt</a>, <a href="#ak_005">Note 6 - Fair Value of Financial Instruments</a>, <a href="#ak_006">Note 7 - Commitments and Contingencies</a>, <a href="#ak_008">Note 9 - Stock-based Compensation</a>, and <a href="#ak_010">Note 11 – Income Taxes</a>. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets, liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zS9fiHdsYYcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zGL1QDng9Ylk">Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking and time deposit accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held. The Company’s deposits were primarily held in Silicon Valley Bank prior to their closure by regulators; however, the Company was subsequently able to regain full access to all its deposits and moved these to a different financial institution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the U.S. and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of December 31, 2023, based on the evaluation of these factors the Company did not record an allowance for doubtful accounts. Phexxi is distributed primarily through three major distributors and a mail-order pharmacy, who receive service fees calculated as a percentage of the gross sales, and a fee per units shipped, respectively. These entities are not obligated to purchase any set number of units and distribute Phexxi on demand as orders are received. For the years ended December 31, 2023, and 2022, the Company’s three largest customers combined made up approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvwL3p5ncja9">84</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWCjTPti6iD8">77</span>% of its gross product sales, respectively. As of December 31, 2023, the Company’s three largest customers combined made up <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zy31tVvaF08i">87</span>% and as of December 31, 2022, the Company’s four largest customers combined made up <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FourLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNoBfk8DHeri" title="Concentration risk, percentage">81</span>% of its trade accounts receivable balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000000.0	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2769000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	580000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1207000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	580000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4776000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	520000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	758000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	386000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4142000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	791000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1748000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	1697000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	6648000	usd
CY2023Q4	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	300000	usd
CY2023	EVFM	Additional Inventory Write Down AdditionalInventoryWriteDown	1300000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	100000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	100000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4400000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5400000	usd
CY2023	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	3000000.0	usd
CY2022	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	0	usd
CY2023Q3	us-gaap	Long Term Debt Contingent Payment Of Principal Or Interest LongTermDebtContingentPaymentOfPrincipalOrInterest	The cash payments will be determined based upon the quarterly global net revenue of Phexxi such that if the global net revenue is less than or equal to $5.0 million, the Company will pay 3% of such global net revenues; if the global net revenue is over $5.0 million and less than or equal to $7.0 million, the Company will continue to pay 3% on net revenue up to $5.0 million and 4% on the net revenue over $5.0 million; and if the global net revenue is over $7.0 million, the Company will pay 3% on the net revenue up to $5.0 million, 4% on the net revenue over $5.0 million up to $7.0 million, and 5% on net revenue over $7.0 million. The cash payments were payable beginning in the fourth quarter of 2023. Regardless of the percentage paid, the quarterly cash payment amounts, along with the $1.0 million upfront payment, will be deducted from the Repurchase Price as Applicable Reductions.
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1424071458	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24653925	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	49995000	usd
CY2023	EVFM	Purchase Rights Change In Fair Value PurchaseRightsChangeInFairValue	1253000	usd
CY2023	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	1432000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	52680000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4826763	shares
CY2023	EVFM	Weighted Average Shares Used To Compute Net Loss Attributable To Common Stockholder Basic WeightedAverageSharesUsedToComputeNetLossAttributableToCommonStockholderBasic	984038574	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2021Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50000000	usd
CY2023	EVFM	Milestone Method Revenue Recognized MilestoneMethodRevenueRecognized	100000000.0	usd
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0615
CY2023Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	92700000	usd
CY2023	EVFM	Milestone Method Revenue Recognized MilestoneMethodRevenueRecognized	100000000.0	usd
CY2023Q3	EVFM	Cumulative Net Sales CumulativeNetSales	100000000	usd
CY2023Q3	EVFM	Accrued Interest Agreement Percentage AccruedInterestAgreementPercentage	0.10	pure
CY2023Q4	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	1000000.0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	75300000	usd
CY2023	EVFM	Revalued Amount Extinguishment Of Debt Amount RevaluedAmountExtinguishmentOfDebtAmount	73200000	usd
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2046000	usd
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2048000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	224000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	129000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	2270000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	2177000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10985000	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	7140000	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	31133776	shares
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1195000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2218000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2389000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7129000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1186000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3189000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1203000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3940000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1270000	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	1717000	usd
CY2023Q4	EVFM	Other Other	35000	usd
CY2022Q4	EVFM	Other Other	331000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4118000	usd
CY2023Q4	EVFM	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	2498000	usd
CY2022Q4	EVFM	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	2574000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1146000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	674000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	583000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	876000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4227000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4124000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2612000	usd
	EVFM	Number Of Leased Vehicles NumberOfLeasedVehicles	21	integer
CY2019Q4	EVFM	Office Square Footage OfficeSquareFootage	24474	sqft
CY2020Q2	EVFM	Office Square Footage OfficeSquareFootage	8816	sqft
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4200000	usd
CY2023Q2	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	200000	usd
CY2022Q2	EVFM	Lessee Operating Sublease Rentable Area LesseeOperatingSubleaseRentableArea	16637	sqft
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
CY2022Q2	us-gaap	Operating Leases Of Lessor Contingent Rentals Basis Spread On Variable Rate OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate	0.035	pure
CY2023	us-gaap	Sublease Income SubleaseIncome	300000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	600000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	826000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1693000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M4D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	47000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	62000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	114000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	105000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1524000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2639000	usd
CY2023	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	0	usd
CY2022	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	1000000.0	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	2100000	usd
CY2023Q4	EVFM	Accounts Payable Trade90 Days Past Due Or More Percent AccountsPayableTrade90DaysPastDueOrMorePercent	0.90	pure
CY2023Q4	EVFM	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	21053694	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.43
CY2023Q4	EVFM	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	21053694	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	EVFM	Exchange Agreement Number Of B2 Series Convertible Shares To Be Redeemed ExchangeAgreementNumberOfB2SeriesConvertibleSharesToBeRedeemed	2100	shares
CY2022Q2	EVFM	Exchange Agreement Number Of C Series Convertible Shares To Be Redeemed ExchangeAgreementNumberOfCSeriesConvertibleSharesToBeRedeemed	1700	shares
CY2023Q3	EVFM	Debt Instrument Redemption Premium In Event Of Default DebtInstrumentRedemptionPremiumInEventOfDefault	0.25	pure
CY2023	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	1800000	usd
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q1	EVFM	Debt Instrument Convertible Beneficial Ownership Limitation Minimum DebtInstrumentConvertibleBeneficialOwnershipLimitationMinimum	0.0499	pure
CY2022Q1	EVFM	Debt Instrument Convertible Beneficial Ownership Limitation Maximum DebtInstrumentConvertibleBeneficialOwnershipLimitationMaximum	0.1999	pure
CY2023Q4	EVFM	Common Stock Reserved Upon Exercise Of Stock Options Outstanding CommonStockReservedUponExerciseOfStockOptionsOutstanding	3747	shares
CY2023Q4	EVFM	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	21053694	shares
CY2023Q4	EVFM	Common Stock Capital Share Reserved For Future Issuance CommonStockCapitalShareReservedForFutureIssuance	385312084	shares
CY2023Q4	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	616497236	shares
CY2023Q4	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	30472989	shares
CY2023Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	370731708	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1424078365	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1189000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3313000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5672	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7761.25
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1925	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9363.75
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3747	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6950.00
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3747	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6950.00
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3153	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7798.75
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	645.00
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.025	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.030	pure
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	52996000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-76654000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	52996000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76654000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-17000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-44000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-17000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-44000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0039	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0212	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0023	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0041	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0304	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0182	pure
CY2023	EVFM	Effective Income Tax Rate Reconciliation Change In Fair Value Of Purchase Rights EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPurchaseRights	-0.0193	pure
CY2022	EVFM	Effective Income Tax Rate Reconciliation Change In Fair Value Of Purchase Rights EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPurchaseRights	0.2260	pure
CY2023	EVFM	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	-0.2717	pure
CY2022	EVFM	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantsPercent	-0.2000	pure
CY2023	EVFM	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	0.0018	pure
CY2022	EVFM	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	-0.0047	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0044	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0141	pure
CY2023	EVFM	Effective Income Tax Rate Reconciliation Accrual Of Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationAccrualOfUncertainTaxPositions	0.0012	pure
CY2022	EVFM	Effective Income Tax Rate Reconciliation Accrual Of Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationAccrualOfUncertainTaxPositions	-0.0039	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0537	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2411	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0001	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0007	pure
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	130746000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	126056000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	246000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	338000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4067000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4951000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6320000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6136000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2513000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3367000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1098000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2247000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	144990000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	143095000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	22000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1011000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	156000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	113000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-27000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-29000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	144785000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	141942000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2988000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2679000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	55000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	5000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	304000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3051000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2988000	usd

Files In Submission

Name	View Source	Status
0001493152-24-011404-index-headers.html	Edgar Link	pending
0001493152-24-011404-index.html	Edgar Link	pending
0001493152-24-011404.txt	Edgar Link	pending
0001493152-24-011404-xbrl.zip	Edgar Link	pending
evfm-20231231.xsd	Edgar Link	pending
evfmtsr_001.jpg	Edgar Link	pending
ex19-1.htm	Edgar Link	pending
evfm-20231231_cal.xml	Edgar Link	unprocessable
evfm-20231231_def.xml	Edgar Link	unprocessable
evfm-20231231_lab.xml	Edgar Link	unprocessable
evfm-20231231_pre.xml	Edgar Link	unprocessable
ex19-2.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_1.jpg	Edgar Link	pending
form10-k_2.jpg	Edgar Link	pending
form10-k_3.jpg	Edgar Link	pending
form10-k_4.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.gif	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
netloss_001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2024 Q1 Form 10-K Financial Statement

#000149315224011404 Filed on March 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2024 Q1 Form 10-K Financial Statement

#000149315224011404 Filed on March 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm